How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

167 results for

HIV related Myelopathy

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. Ofatumumab Dose-finding in Relapsing Remitting Multiple Sclerosis (RRMS) Patients

=moderate AE; G 3=severe AE; G 4=life-threatening or disabling AE; G 5=death related to AE. Number of Participants With Negative or Unconfirmed Human Anti-human Antibodies (HAHA) in Which Concentrations of Ofa Were Below 500 Nanograms Per Milliliter (ng/ml) [ Time Frame: Visit 3 (Week 0), Visit 10 (Week 24), Visit 17 (Week 48) or early withdrawal (EW), and Visit 26 (Week 104) ] Participants are checked for negative (or a lack of) HAHA at Baseline, and then throughout the study, to ensure (...) : A Double-blind, Randomized, Placebo Controlled, Multicenter, Dose-finding Trial of Ofatumumab in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Study Start Date : May 2008 Actual Primary Completion Date : May 2010 Actual Study Completion Date : October 2011 Resource links provided by the National Library of Medicine related topics: related topics: available for: Arms and Interventions Go to Arm Intervention/treatment Experimental: Cohort 1.1 100mg ofatumumab then placebo Drug: Ofatumumab 100

2008 Clinical Trials

142. Freedom Lumbar Disc in the Treatment of Lumbar Degenerative Disc Disease

Resource links provided by the National Library of Medicine related topics: Arms and Interventions Go to Arm Intervention/treatment Experimental: Treatment FLD Device: FLD Artificial lumbar disc Active Comparator: Control Device: Control Artificial lumbar disc Outcome Measures Go to Primary Outcome Measures : Overall success will be determined by a composite of measures regarding subject self-assessment of function (disability), low back pain, neurological function and device implantation status (...) is a surgical candidate for an anterior approach to the lumbar spine (<3 abdominal surgeries). Back pain at the operative level only (by discogram, if necessary). Leg pain and/or back pain due to disc space settling, with or without radicular symptoms related to foraminal narrowing. Subject must understand and sign the written Informed Consent. Exclusion Criteria: Prior fusion at any lumbar level. Clinical evidence of adjacent lumbar segment disease. Previous trauma to the L3, L4, L5, or S1 levels

2008 Clinical Trials

143. An Assessment of P-15 Bone Putty in Anterior Cervical Fusion With Instrumentation

-binding domain of Type I human collagen and is responsible for osteogenic cell attachment via alpha2-beta1 integrins. This is randomized, controlled, multi-center, prospective FDA IDE study conducted to assess the safety and effectiveness of i-FACTOR bone graft (Cerapedics, Inc. Westminster, CO) in patients treated with single level ACDF. Patients received i-FACTOR bone graft or local autologous bone inside a structural allograft. Study Design Go to Layout table for study information Study Type (...) : Interventional (Clinical Trial) Actual Enrollment : 319 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: Single (Participant) Primary Purpose: Treatment Official Title: An Assessment of P-15 Bone Putty in Anterior Cervical Fusion With Instrumentation Study Start Date : January 2006 Actual Primary Completion Date : May 2014 Estimated Study Completion Date : May 2019 Resource links provided by the National Library of Medicine related topics: Arms and Interventions Go to Arm

2006 Clinical Trials

144. Evolution of Pain From Herpes Zoster

Criteria: The AHZ outbreak is complicated by stroke or myelopathy. Patients with facial or cranial AHZ. Patients with signs of spinal cord or brainstem injury from HZ. Patients who are considered unreliable as to study compliance or adherence to scheduled appointments as determined by the Investigators. Patients, who are undergoing active treatment for cancer, are infected with the Human Immunodeficiency Virus, or are being acutely and intensively immunosuppressed following a transplantation procedure (...) and innervation abnormalities. Study Design Go to Layout table for study information Study Type : Observational Estimated Enrollment : 100 participants Observational Model: Cohort Time Perspective: Prospective Official Title: Evolution of Pain and Neural Dysfunction From Acute Herpes Zoster to Post-Herpetic Neuralgia Study Start Date : November 2001 Actual Primary Completion Date : November 2005 Actual Study Completion Date : December 2006 Resource links provided by the National Library of Medicine related

2006 Clinical Trials

145. Acute Safety, Tolerability, Feasibility and Pharmacokinetics of Intrath. Administered ATI355 in Patients With Acute SCI

(exception: history of uncomplicated Hepatitis A), gastrointestinal, cardiac, immunodeficiency (including human immunodeficiency virus [HIV]) or kidney disease; or active malignancy or any other condition as determined by history or laboratory investigation that could cause a neurological deficit including syphilis, myelopathy, clinically relevant polyneuropathy, etc. History of meningitis, meningoencephalitis, epilepsy or life-threatening allergic or immune-mediated reaction. History of or current (...) Start Date : May 2006 Actual Primary Completion Date : September 2011 Actual Study Completion Date : September 2011 Resource links provided by the National Library of Medicine related topics: Arms and Interventions Go to Arm Intervention/treatment Experimental: 1 Drug: ATI355 Outcome Measures Go to Primary Outcome Measures : Feasibility, Safety and Tolerability of a continuous intrathecal (i.t.) infusion or i.t. repeated bolus injections of ATI355 in patients with acute spinal cord injury at every

2006 Clinical Trials

146. Human T-lymphotropic virus type II and neurological disease. (Abstract)

Human T-lymphotropic virus type II and neurological disease. Human T-lymphotropic virus type I (HTLV-I) and type II (HTLV-II) are closely related retroviruses with similar biological properties and common modes of transmission. HTLV-I infection is endemic in well-defined geographic regions, and it is estimated that some 20 million individuals are infected worldwide. Although most infected individuals are asymptomatic carriers, some 2 to 5% will develop a chronic encephalomyelopathy, HTLV-I (...) similar or identical to HAM/TSP. However, most reports that have attributed infection to a range of other neurological disorders are difficult to evaluate in that in many cases either the association appears to be fortuitous or the presentations were confounded by a background of concomitant human immunodeficiency virus-1 infection and/or active IDU. In view of the many HTLV-II-infected individuals in urban areas of North America and Europe, neurologists should be aware of the potential clinical

2004 Annals of Neurology

147. Motor Neurone Disease

. There is pain (localised to the neck or radicular) and sensory disturbance. There are no bulbar symptoms and signs. The absence of UMN signs above the LMN signs increases the possibility of this diagnosis. MRI scan of the cervical spine can confirm the diagnosis. Dual pathologies: A cervical myelopathy and a co-existent peripheral neuropathy can present as a mixed upper-lower motor neurone picture. Sensory signs and symptoms and absence of bulbar symptoms help to diagnose this. Neurophysiological assessment (...) with associated . . . . . HIV-associated neuropathy/myopathy/radiculopathy (as one of the complications of HIV). Lepto-meningeal disease - eg, due to carcinomatosis or vascular collagen disease. . (Kennedy's syndrome). Hereditary polyneuropathies - eg, . Focal muscular atrophies (monomelic amyotrophy). Post-radiation myeloplexopathy. Viral plexopathies. (adult form). Investigations [ ] There are no specific investigations that will confirm a diagnosis of MND. A range of investigations is carried out

2008 Mentor

148. Cervical Spondylosis

of movement (forward flexion, backward extension, lateral flexion and rotation to both sides). Minor neurological changes like inverted supinator jerks (unless complicated by myelopathy or radiculopathy). Poorly localised tenderness. Radiculopathy [ ] Suspect this where there is unilateral neck, shoulder, or arm pain approximating to a dermatome. There may be accompanying changes in sensation or weakness in related muscles. NB : pain or paraesthesia radiating into the arm is a nonspecific sign for nerve (...) sweats. Unexpected weight loss. History of inflammatory arthritis, malignancy, infection, tuberculosis, HIV infection, drug dependency, or immunosuppression. Excruciating pain. Intractable night pain. Cervical lymphadenopathy. Exquisite tenderness over a vertebral body. Features suggestive of a myelopathy include: Insidious progression. Gait disturbance +/- clumsy hands. Loss of sexual, bladder or bowel function (often a late sign). Lhermitte's sign (neck flexion causes 'electric shock'-type

2008 Mentor

149. Abbreviations

Medicines CHMP Committee for Medicinal Products for Human Use CI confidence interval CIRCI critical illness-related corticosteroid insufficiency CIS carcinoma in situ cm centimetre CMACE Centre for Maternal and Child Enquiries CNS central nervous system CNV choroidal neovascularisation COAD chronic obstructive airways disease COCP combined oral contraceptive pill COPD chronic obstructive pulmonary disease COMT catechol-O-methyltransferase COSHH Committee on Substances Hazardous to Health COT (...) and neurological deficits + CSF lymphocytosis HAV hepatitis A virus HAVS hand-arm vibration syndrome HBcAg hepatitis B core antigen HBeAg hepatitis B e antigen HBsAg hepatitis B surface antigen HCTD hereditary connective tissue disorders HDCV human diploid cell vaccine HFNEF heart failure with a normal ejection fraction HFPSF heart failure with preserved systolic function HGPRT hypoxanthine guanine phosphoribosyltransferase Hib Haemophilus influenzae type b HIDA hepatobiliary imino-diacetic acid HIFU high

2008 Mentor

150. Intranasal Peptide T in the Treatment of Painful Peripheral Neuropathy of AIDS

Trials Information Service Study Details Study Description Go to Brief Summary: To compare the effects of intranasal peptide T and placebo in the treatment of painful peripheral neuropathy associated with human immunodeficiency virus (HIV) infection. Condition or disease Intervention/treatment Phase HIV Infections Peripheral Nervous System Disease Drug: Peptide T Not Applicable Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Primary Purpose (...) to Publications: MacFadden DK, Doob PR. Role of peptide T in palliation of HIV-1-related painful peripheral neuropathy. Int Conf AIDS. 1991 Jun 16-21;7(2):225 (abstract no WB2173) Layout table for additonal information ClinicalTrials.gov Identifier: Other Study ID Numbers: 115A 01 First Posted: August 31, 2001 Last Update Posted: June 24, 2005 Last Verified: March 1993 Keywords provided by NIH AIDS Clinical Trials Information Service: Peptide T HIV-1 Administration, Intranasal Acquired Immunodeficiency

1999 Clinical Trials

151. Evaluation of Patients With HAM/TSP

): National Institutes of Health Clinical Center (CC) ( National Institute of Neurological Disorders and Stroke (NINDS) ) Study Details Study Description Go to Brief Summary: Objective: Human T-lymphotropic virus type-I-associated myelopathy / tropical spastic paraparesis (HAM/TSP) is a rare neurologic disorder that affects less than 5% of patients infected with the HTLV-I virus. The purpose of this protocol is to study the natural history of HAM/TSP by monitoring clinical progression of patients (...) T-lymphotropic virus type-I-associated myelopathy / tropical spastic paraparesis (HAM/TSP) is a rare neurologic disorder that affects less than 5% of patients infected with the HTLV-I virus. Recently, a large body of literature supports other inflammatory manifestations, some neurological such as myositis, due to HTLV-1 infection. Studies of HLTV-2 clinical manifestations have largely been confounded by concomitant HIV-1 infection or IV drug abuse making the establishment of clear relationship

1999 Clinical Trials

152. Study and Surgical Treatment of Syringomyelia

as determined by a radiologist. They have a problem with bleeding that cannot be corrected. They are unable to understand the risks of the testing and surgical therapy. Their blood test for HIV (the virus that causes AIDS) is positive, because a positive HIV test would increase your risk of infection from research testing. They have syringomyelia which developed after meningitis, because we have found that laminectomy and duroplasty is ineffective in this setting Contacts and Locations Go to Information (...) spinal subarachnoid pressure waves occur with every heartbeat and act on the spinal cord above the block to drive CSF into the spinal cord and create a syrinx. Presyringomyelia, a recently described state of spinal cord edema associated with progressive myelopathy and obstruction in CSF flow, is a precursor stage to syringomyelia that is consistent with this hypothesis. Because of the importance of this condition to the pathophysiology of syringomyelia, we will also study patients

2001 Clinical Trials

153. Acetyl-L-Carnitine for the Treatment of NRTI-Associated Peripheral Neuropathy

) or OI-defining condition within 30 days prior to entry Any condition or history of any condition, other than that related to HIV infection or antiretroviral therapy, that would add confusion to the diagnosis of dideoxynucleoside analogue-associated DSPN Pregnancy or breast-feeding Active malignancy Seizure disorder or history of seizure within 90 days of entry Current or history of bipolar disorder Certain drugs within 30 days of study entry Addition of certain pain medication during the 60 days (...) by National Institute of Allergy and Infectious Diseases (NIAID): Acetylcarnitine Dideoxynucleosides Epidermis Biopsy Immunohistochemistry Nerve Fibers Treatment Experienced Additional relevant MeSH terms: Layout table for MeSH terms HIV Infections Peripheral Nervous System Diseases Nervous System Diseases Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System

2002 Clinical Trials

154. Clinical standards & management of acquired syphilis in HIV-positive patients

disease and human immunodeficiency virus screening guidelines for men who have sex with men. Sex Transm Dis 2001; in press and at www.metrkc.gov/health/apu/std 15.California Sexually Transmitted Disease Controllers Association. Guidance for STD clinical preventive services for persons infected with HIV. Sex Transm Dis 2001; in press.Draft v.8 21.2.02 Page 9 16. CDSC. Increased transmission of syphilis in Brighton and Greater Manchester among men who have sex with men. Commun Dis Rep CDR Wkly 2000;10 (...) (43):383-386. 17. Becerra LI, Ksiazek SM, Savino PJ, et al. Syphilitic uveitis in human immunodeficiency virus-infected and non-infected patients. Ophthalmology 1989;96:1727- 1730. 18. Berger JR. Neurosyphilis in human immunodeficiency virus type 1-seropositive individuals. Arch Neurol 1991;48:700-702. 19. Bordon J, Martinez-Vazquez C, Alvarez M, et al: Neurosyphilis in HIV-infected patients. Eur J Clin Microbiol Infect Dis 1995;14:864-869. 20. Nandwani R, Evans DTP. Are you sure it’s syphilis

2002 British Association for Sexual Health and HIV

155. Epoetin Alfa for HIV-Associated Neuropathy Trial

out clinical trials to improve the therapy for HIV induced neurologic disease, and neurologic conditions associated with the AIDS virus. Complications of HIV are dynamically evolving over time. In general, neurologic complications that typically occur in advanced disease stages are increasing in incidence while some of the early complications associated with AIDS are less commonly found due to improved preventive therapy. The impact of the new generation of antiretroviral drugs (...) ) or OI-defining condition £30 days from Visit 1. Subject has active major disease, both HIV-related and non-HIV-related including, but not limited to, cardiac disease, pulmonary, or hepatorenal, which in the opinion of the investigator might affect the study. Subject is pregnant or breast-feeding. Subject has any currently active malignancy, or a history of any previous malignancy with the exception of skin squamous cell carcinoma or basal cell carcinoma. Subject has received any investigational

2007 Clinical Trials

156. Complications of HIV Infection

and European Guidelines. You may find the article more useful, or one of our other . In this article In This Article Complications of HIV Infection In this article Most complications of HIV/AIDS are as a result of suppression of T cell-mediated immunity. Antiretroviral therapy (ART) is available to inhibit the replication of the human immunodeficiency virus. [ ] ART is increasingly replacing the term 'highly active antiretroviral therapy' (HAART) in common usage. ART helps to prolong life, restore (...) neuropathy. Neurol Clin. 2008 Aug26(3):821-32, x. ; HIV peripheral neuropathy. Handb Clin Neurol. 2013115:515-29. doi: 10.1016/B978-0-444-52902-2.00029-1. ; The search for new therapies for human cytomegalovirus infections. Virus Res. 2011 May157(2):212-21. Epub 2010 Nov 21. ; Medical Foundation for AIDS & Sexual Health (2011) ; Incidence and timing of cancer in HIV-infected individuals following initiation of combination antiretroviral therapy. Clin Infect Dis. 2013 Sep57(5):756-64. doi: 10.1093/cid

2008 Mentor

157. Phase I Rising Dose Tolerability Study of SC-48334 in Patients With Acquired Immunodeficiency Syndrome (AIDS) and Advanced AIDS Related Complex

AIDS-Related Complex Antiviral Agents Biological Availability 1-Deoxynojirimycin Additional relevant MeSH terms: Layout table for MeSH terms HIV Infections Immunologic Deficiency Syndromes Acquired Immunodeficiency Syndrome AIDS-Related Complex Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immune System Diseases Slow Virus Diseases Miglustat Enzyme Inhibitors Molecular Mechanisms (...) Phase I Rising Dose Tolerability Study of SC-48334 in Patients With Acquired Immunodeficiency Syndrome (AIDS) and Advanced AIDS Related Complex Phase I Rising Dose Tolerability Study of SC-48334 in Patients With Acquired Immunodeficiency Syndrome (AIDS) and Advanced AIDS Related Complex - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save

1999 Clinical Trials

158. A Phase II, Double-Blind Trial of Recombinant Human Nerve Growth Factor for Treatment of HIV-Associated Sensory Neuropathy

Study Type : Interventional (Clinical Trial) Enrollment : 270 participants Masking: Double Primary Purpose: Treatment Official Title: A Phase II, Double-Blind Trial of Recombinant Human Nerve Growth Factor for Treatment of HIV-Associated Sensory Neuropathy Actual Study Completion Date : February 1999 Resource links provided by the National Library of Medicine related topics: available for: Arms and Interventions Go to Outcome Measures Go to Eligibility Criteria Go to Information from the National (...) A Phase II, Double-Blind Trial of Recombinant Human Nerve Growth Factor for Treatment of HIV-Associated Sensory Neuropathy A Phase II, Double-Blind Trial of Recombinant Human Nerve Growth Factor for Treatment of HIV-Associated Sensory Neuropathy - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached

1999 Clinical Trials

159. A Phase II/III Double-Blind Study of Amitriptyline and Mexiletine for Painful Neuropathy in HIV Infection

Immunodeficiency Syndrome AIDS-Related Complex Peripheral Nervous System Diseases Amitriptyline Pain Mexiletine benzatropine methanesulfonate Parasympatholytics Additional relevant MeSH terms: Layout table for MeSH terms Infection Communicable Diseases HIV Infections Acquired Immunodeficiency Syndrome Nervous System Diseases Peripheral Nervous System Diseases Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases (...) : April 3, 2012 Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Collaborator: Boehringer Ingelheim Information provided by (Responsible Party): National Institute of Allergy and Infectious Diseases (NIAID) Study Details Study Description Go to Brief Summary: To assess the efficacy, safety, and tolerability of amitriptyline hydrochloride versus mexiletine hydrochloride in reducing pain intensity in patients with HIV-related painful peripheral neuropathy. No large-scale controlled

1999 Clinical Trials

160. Progressive neurological dysfunction during latent HIV infection. Full Text available with Trip Pro

Progressive neurological dysfunction during latent HIV infection. OBJECTIVE--To determine whether the delayed conduction through the spinal cord and peripheral nerves seen in patients with AIDS is related to infection with HIV or to the presence of an immunodeficient state. DESIGN--Two year prospective follow up study of electrophysiological measurements in subjects positive for HIV antibody but without AIDS. SETTING--HIV screening clinic and clinical departments in a university hospital (...) %). The conduction time from the gluteal crease to T12 was increased by a mean of 32.0% (5.0%) whereas that in the median and tibial nerves by only 5.6% (1.0%) and 2.2% (2.2%) respectively. CONCLUSIONS--A mild and slowly progressive peripheral neuropathy of the axonal type and a more severe progressive myelopathy or myeloradiculopathy occur concomitantly with early HIV infection, possibly as the result of a direct neurotropic action of HIV.

1989 BMJ : British Medical Journal

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>